Ozempic / GLP-1 Lawsuits Statistics in Birmingham
~1.1 million
Metro Population
~37%
Adult Obesity Rate (Jefferson Co.)
2 years from discovery
AL SOL
Daubert
Expert Standard
Courts in Birmingham, Alabama
Jefferson County Circuit Court
716 Richard Arrington Jr Blvd N, Birmingham, AL 35203
U.S. District Court, Northern District of Alabama
1729 5th Ave N, Birmingham, AL 35203
Hospitals & Trauma Centers in Birmingham
UAB Hospital — Gastroenterology & Hepatology
619 19th St S, Birmingham, AL 35233
Grandview Medical Center
3690 Grandview Pkwy, Birmingham, AL 35243
Liability Considerations in Birmingham
Ozempic Litigation in Birmingham
Birmingham's medical community has documented a significant increase in gastroparesis cases coinciding with the surge in GLP-1 prescriptions. UAB's gastroenterology division has expertise in GI motility disorders and can provide the gastric emptying studies that are critical evidence in GLP-1 litigation. The August 2025 MDL ruling requiring confirmed gastric emptying studies at diagnosis makes UAB's diagnostic capabilities particularly important for Birmingham-area claimants. Cases are consolidated in MDL 3094 (E.D. Pennsylvania) before Judge Karen S. Marston, with bellwether trials expected in mid-to-late 2026. Novo Nordisk and Eli Lilly are the primary defendants. Birmingham claimants who used Ozempic, Wegovy, or Mounjaro and developed gastroparesis, bowel obstruction, pancreatitis, or gallbladder disease should gather pharmacy records and medical documentation before consulting an attorney.